trol and Prevention in expanding its partnerships 
with States and Indian Tribes and provide technical 
assistance to existing Maternal Mortality Review 
Committees; 
(3) $45,000,000 for the Pregnancy Risk As-
sessment Monitoring System (commonly known as 
the ‘‘PRAMS’’) of the Centers for Disease Control 
and Prevention, to support the Centers for Disease 
Control and Prevention in its efforts to— 
(A) create a COVID–19 supplement to its 
PRAMS questionnaire; 
(B) add questions around experiences of 
respectful, responsive, and empowering mater-
nity 
care 
in 
prenatal, 
intrapartum, 
and 
postpartum care; 
(C) 
conduct 
a 
rapid 
assessment 
of 
COVID–19 awareness, impact on care and ex-
periences, and use of preventive measures 
among pregnant, laboring and birthing, and 
postpartum people during the COVID–19 pub-
lic health emergency; and 
(D) work to transition the survey to an 
electronic platform and expand the survey to a 
larger population, with a special focus on reach-
ing underrepresented communities and under-
VerDate Sep 11 2014 
03:32 Dec 30, 2022
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H9602.IH
H9602
kjohnson on DSK79L0C42PROD with BILLS
served communities, and with sensitivity to in-
dividuals who lack access to such a platform; 
and 
(4) $15,000,000 for the National Institute of 
Child Health and Human Development, to conduct 
or support research for interventions to mitigate the 
effects of the COVID–19 public health emergency on 
pregnant and postpartum people, including Black, 
Latinx, Asian-American and Pacific Islander, and 
American Indian and Alaska Native people, as well 
as people living in areas with limited maternity care. 
SEC. 5. COVID–19 MATERNAL HEALTH DATA COLLECTION 
AND DISCLOSURE. 
(a) DATA
COLLECTION.—The Secretary, acting 
through the Director of the Centers for Disease Control 
and Prevention and the Administrator of the Centers for 
Medicare & Medicaid Services, shall make publicly avail-
able, on the website of the Centers for Disease Control 
and Prevention, pregnancy and postpartum data collected 
across all surveillance systems relating to COVID–19, 
disaggregated by race, ethnicity, primary language, dis-
ability status, gender identity, sexual orientation, immi-
gration status, insurance status, and State and Tribal lo-
cation, including the following: 
VerDate Sep 11 2014 
03:32 Dec 30, 2022
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H9602.IH
H9602
kjohnson on DSK79L0C42PROD with BILLS
(1) Data related to all COVID–19 diagnostic 
testing, including the number of pregnant people 
and postpartum people tested and the number of 
positive cases. 
(2) Data related to all suspected cases of 
COVID–19 in pregnant, birthing, and postpartum 
people who did not undergo testing. 
(3) Data related to all COVID–19 serologic 
testing, including the number of pregnant and 
postpartum people tested and the number of such 
serologic tests that were positive. 
(4) Data related to treatment for COVID–19, 
including hospitalizations, emergency room, and in-
tensive care unit admissions of pregnant, birthing, 
and postpartum people related to COVID–19. 
(5) Data related to COVID–19 outcomes, in-
cluding total fatalities and case fatality (expressed 
as the proportion of people who were infected with 
COVID–19 and died from the virus) of pregnant 
and postpartum people. 
(6) Data related to pregnancy and infant health 
outcomes for pregnant people with confirmed or sus-
pected COVID–19, which may include stillbirths, 
maternal mortality and morbidity, infant mortality, 
VerDate Sep 11 2014 
03:32 Dec 30, 2022
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H9602.IH
H9602
kjohnson on DSK79L0C42PROD with BILLS
preterm births, low-birth weight infants, and cesar-
ean section births. 
(7) Data related to all long-term effects of 
COVID–19 related to cases contracted during the 
pregnancy or postpartum period. 
(b) TIMELINE.—The Secretary shall update the data 
made available under this section not less frequently than 
monthly, during the COVID–19 public health emergency 
and for at least one month after the end of the COVID– 
19 public health emergency. 
(c) PRIVACY.—In publishing data under this section, 
the Secretary shall take all necessary steps to protect the 
privacy of people whose information is included in such 
data, including by complying with— 
(1) privacy protections under the regulations 
promulgated under section 264(c) of the Health In-
surance Portability and Accountability Act of 1996 
(42 U.S.C. 1320d–2 note); and 
(2) protections from all inappropriate internal 
use by an entity that collects, stores, or receives the 
data, including use of such data in determinations of 
eligibility (or continued eligibility) in health plans, 
and from inappropriate uses. 
(d) INDIAN HEALTH SERVICE.—The Director of the 
Indian Health Service and Director of the Centers for Dis-
VerDate Sep 11 2014 
03:32 Dec 30, 2022
Jkt 039200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H9602.IH
H9602
kjohnson on DSK79L0C42PROD with BILLS
ease Control and Prevention shall consult with Indian 
Tribes and confer with urban Indian organizations on data 
collection and reporting for purposes of this section. 
(e) DATA COLLECTION GUIDANCE.—The Secretary 
shall issue guidance to States and local public health de-
partments to ensure that all relevant demographic data, 
including pregnancy and postpartum status, are collected 
and included when sending COVID–19 testing specimen 
to laboratories, and State and local health departments 
and Indian Tribes are disaggregating data on COVID–19 
status in data on maternal and infant morbidity and mor-
tality. The Secretary shall ensure that the guidance is de-
veloped in consultation with Indian Tribes to ensure that 
it includes Tribally developed best practices on reducing 
misclassification of American Indian and Alaska Native 
people in Federal, State, and local public health surveil-
lance systems. 
SEC. 6. PUBLIC HEALTH COMMUNICATION REGARDING MA-
TERNAL CARE DURING COVID–19. 
(a) PUBLIC HEALTH CAMPAIGN.—The Director of 
the Centers for Disease Control and Prevention shall un-
dertake a robust public health education effort to enhance 
access by pregnant people, their employers, and their pro-
viders to accurate, evidence-based health information 
about COVID–19 and pregnancy, safety, and risk, with 
VerDate Sep 11 2014 
03:32 Dec 30, 2022
Jkt 039200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H9602.IH
H9602
kjohnson on DSK79L0C42PROD with BILLS